Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program PR Newswire WALTHAM, Mass., Dec. 10, 2024 -- SIGNAL-AA demonstrated encouraging...
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov. 7, 2024 -- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and...
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PR Newswire WALTHAM, Mass., Nov. 5, 2024 WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB...
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 PR Newswire WALTHAM, Mass., Oct. 14...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4319 | -11.5790884718 | 3.73 | 3.8 | 3.02 | 790745 | 3.41758601 | CS |
4 | -21.3619 | -86.6257096513 | 24.66 | 28.66 | 3.02 | 697727 | 6.7612968 | CS |
12 | -42.7519 | -92.8380021716 | 46.05 | 53.17 | 3.02 | 286213 | 14.80554558 | CS |
26 | -12.2519 | -78.7903536977 | 15.55 | 53.79 | 3.02 | 192309 | 21.51368367 | CS |
52 | -12.9419 | -79.6915024631 | 16.24 | 53.79 | 3.02 | 145067 | 21.81043989 | CS |
156 | -12.9419 | -79.6915024631 | 16.24 | 53.79 | 3.02 | 145067 | 21.81043989 | CS |
260 | -12.9419 | -79.6915024631 | 16.24 | 53.79 | 3.02 | 145067 | 21.81043989 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.